Complete Omics

Complete Omics is a United States-based molecular diagnostics and life sciences company headquartered in Baltimore, Maryland. According to its official website, the company describes itself as a CLIA-certified and CAP-accredited omics platform for research and care, engineering what it calls the next foundational layer of molecular diagnostics: ultra-deep, clinically reproducible proteomics integrated with multi-omics architectures and AI-driven analytics. Rather than positioning itself as a conventional research laboratory, Complete Omics presents its work as building scalable molecular infrastructure that transforms complex biological signals into earlier disease detection, therapeutic guidance, and system-level clinical intelligence. The company's stated focus spans both wet-lab and computational domains. Its wet-lab operations are oriented toward generating gold-standard clinical data engineered for reproducibility, scale, and regulatory trust, while its proprietary AI systems are designed to analyze large-scale, high-dimensional biological data and convert it into actionable clinical intelligence. Complete Omics also describes direct patient-facing and care-oriented platforms that connect diagnostics with clinical decision-making. On the diagnostics side, Complete Omics organizes its medical testing services around four disease categories: oncology, neurology, cardiovascular disease, and immunology. Its oncology offerings include multiple myeloma monitoring and disease stratification, prostate cancer risk assessment beyond PSA alone, and multi-cancer detection panels with integrated multi-omics architecture. The company states that its assays are CPT-coded, insurance-covered, and actively deployed in clinical practice, and that programs are built from inception with analytical validation, reimbursement feasibility, and scalability in mind. Popular tests listed on its website include a multiple myeloma test, a heart failure test, prostate cancer screening, and personalized neoantigen assays. The company reports backing by more than 40 global patents and publications in top-tier journals including Cell, Nature, and Science, along with more than 70 additional high-impact specialty publications. Its oncology panel development is described as being directly supervised by founder and scientist Qing Wang, PhD. Complete Omics is headquartered at 1448 South Rolling Rd Ste 218, Baltimore, MD 21227, and can be reached through its official website and contact channels. As a privately held diagnostics company, it operates at the intersection of proteomics, multi-omics, artificial intelligence, and regulated clinical testing.

Complete Omics is a privately held molecular diagnostics company based in Baltimore, Maryland, United States. Public information about its early corporate history is limited, but its official website and Wikidata entry establish it as a company operating in the life sciences and clinical diagnostics space. The company has built its identity around the convergence of ultra-deep proteomics, multi-omics, and artificial intelligence, describing its mission as engineering the next foundational layer of molecular diagnostics. From its base in Baltimore, Complete Omics has developed and marketed medical testing services organized around four disease categories: oncology, neurology, cardiovascular disease, and immunology. Its oncology programs include multiple myeloma monitoring and disease stratification, prostate cancer risk assessment beyond PSA alone, and multi-cancer detection panels with integrated multi-omics architecture. The company states that its assays are CPT-coded, insurance-covered, and actively deployed in clinical practice, and that its laboratory operates under CLIA certification and CAP accreditation. The company reports that its work is supported by more than 40 global patents and publications in top-tier journals including Cell, Nature, and Science, along with more than 70 additional high-impact specialty publications. Its oncology panel development is described as being directly supervised by founder and scientist Qing Wang, PhD. Complete Omics also emphasizes direct patient-facing and care-oriented platforms that connect diagnostics with clinical decision-making. As of the available evidence, Complete Omics continues to operate as an active, privately held diagnostics company headquartered at 1448 South Rolling Rd Ste 218, Baltimore, MD 21227. It presents itself as building regulated, execution-ready molecular infrastructure for precision medicine, bridging plasma and tissue, research and clinic, and discovery and deployment.

Complete Omics positions itself as a CLIA-certified, CAP-accredited diagnostics company building regulated, execution-ready molecular infrastructure for precision medicine, bridging proteomics, multi-omics, and AI to deliver clinically reproducible results.

• Multiple Myeloma Test

  Quick and accurate test for multiple myelomas, including monitoring and disease stratification.

• Heart Failure Test

  Comprehensive tests for heart failure and cardiovascular diseases.

• Prostate Cancer Screening

  Prostate cancer diagnostics and stratification, including risk assessment beyond PSA alone.

• Personalized Neoantigen Assays

  Assays for classical and customized personalized neoantigens.

• Multi-Cancer Detection Panels

  Multi-cancer early detection programs with integrated multi-omics architecture.

• COVID-19 and other virus tests

  Testing for COVID-19 and other viruses.

1. 1Complete Omics – CLIA&CAP–Accredited Omics Platform For Research and Carecompleteomics.com
2. 2Contact Us – Complete Omicscompleteomics.com
3. 3Medical Testing – Complete Omicscompleteomics.com
4. 4Oncology – Complete Omicscompleteomics.com
5. 5Complete Omics (United States) – Wikidatawikidata.org